- Evolocumab, proproteine convertase subtilisin/kexin type 9 inhibitor for intensive treatment of dyslipidemia2016 | Faculty of Medicine in Pilsen
- Proprotein convertase subtilisin/kexin type 9 inhibitors in the treatment of a patient with dyslipidemia and myopathy2019 | Third Faculty of Medicine
- Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)2023 | First Faculty of Medicine
- Aktuality ze světa inhibice PCSK92019 | First Faculty of Medicine
- The authors of lipid guidelines are at odds with their own recommendations2017 | First Faculty of Medicine
- Anotation of interesting articles from foreign literature2017 | First Faculty of Medicine
- New possibilities of dyslipidemiaa therapy in patients with familial hypercholesterolemia in secondary prevention - change in reimbursement for PCSK9 inhibitors2021 | First Faculty of Medicine
- Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement2016 | First Faculty of Medicine
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome2020 | Publication without faculty affiliation
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial2020 | Publication without faculty affiliation
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial2019 | Publication without faculty affiliation
- An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial2020 | First Faculty of Medicine
- Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes2019 | Publication without faculty affiliation